Investors looking to capitalize on the current market momentum should keep an eye on these three stocks for potential gains on January 26:
PACCAR Inc (PCAR): This truck manufacturer carries a Zacks Rank #1 and has seen a 5.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days.
PACCAR Inc. Performance
PACCAR’s shares have surged 22.5% in the last three months, outperforming the S&P 500, and boasts a stellar Momentum Score of A.
Inhibikase Therapeutics, Inc
Inhibikase Therapeutics, Inc (IKT): This pharmaceutical company also holds a Zacks Rank #1 and has enjoyed a remarkable 16% increase in the Zacks Consensus Estimate for its current year earnings over the past 60 days.
Inhibikase Therapeutics, Inc. Performance
Inhibikase Therapeutics’s stock has soared a staggering 195.5% in the last three months, leaving the S&P 500’s 18% gain in the dust, demonstrating a Momentum Score of A.
PagerDuty, Inc.
PagerDuty, Inc (PD): This digital operations platform also flaunts a Zacks Rank #1 and has witnessed a 16.1% surge in the Zacks Consensus Estimate for its current year earnings over the last 60 days.
PagerDuty, Inc. Performance
PagerDuty’s shares have climbed 21.8% over the last three months, outshining the S&P 500, and maintains a respectable Momentum Score of B.
For a comprehensive list of top-ranked stocks, click here. To learn more about the Momentum score and its computation, click here.
5 Stocks Set to Double
Each has been handpicked by a Zacks expert as the #1 favorite stock for gaining +100% or more in 2023. Past recommendations have witnessed incredible growth, with some soaring +143.0%, +175.9%, +498.3%, and +673.0%.
Most of the stocks in this report are flying under Wall Street’s radar, representing a lucrative opportunity to get in at the ground floor.
Today, See These 5 Potential Home Runs >>
PACCAR Inc. (PCAR) : Free Stock Analysis Report
PagerDuty (PD) : Free Stock Analysis Report
Inhibikase Therapeutics, Inc. (IKT) : Free Stock Analysis Report
